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PERSPECTIVES ON DRUGS 
Preventing overdose  
deaths in Europe
The heroin epidemics, which spread across Europe in the 
1980s, resulted in increasing numbers of overdose deaths 
among opioid users (1). Although the annual number of 
reported deaths peaked around the turn of the millennium, 
drug overdose still claimed more than 70 000 lives in Europe 
in the subsequent decade. Contrary to the promising overall 
trend between 2009 and 2013, when the number of reported 
overdose deaths fell  from around 7 100 to 6 100, the most 
recent data from a number of countries with relatively robust 
reporting systems, including Germany, Sweden and the United 
Kingdom, show an increase.
Drug overdose continues to be a major cause of death, 
especially among young people in Europe, with recent data 
showing that it accounts for more than 3.4 % of all deaths 
among Europeans between the ages of 15 and 39 (Eurostat, 
2013). European countries have implemented a variety of 
approaches in their attempt to reduce overdose deaths at the 
national level using evidence-based interventions drawing on 
an understanding of individual and environmental risk factors.
I  Which factors increase the risk of fatal and non-fatal overdose?
The type of substance used, the route of administration 
and the health of the user all have an impact on the risk of 
overdose. Most overdose deaths are linked to the use of 
opioids, primarily the injection of heroin. Heightened levels of 
risk are also associated with the misuse of certain prescription 
It is estimated that over 70 000 lives were 
lost to drug overdoses in Europe in the 
first decade of the 21st Century. Reducing 
drug-related deaths, therefore, remains a 
major challenge for public health policy. 
This analysis describes some of the 
factors that increase the risk of fatal and 
non-fatal overdoses and a number of 
interventions developed to prevent these 
events.
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(1 ) In this analysis, the term ‘overdose deaths’ refers to deaths that are caused 
directly by the consumption of one or more illicit drug (http://www.emcdda.europa.
eu/activities/drd). Generally, overdose deaths occur shortly after the consumption 
of the substance(s). These deaths are also known as ‘poisonings’ or ‘drug-induced 
deaths’. 
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drugs (e.g. benzodiazepines), and the non-medical use of 
prescribed substitution medications and opioid analgesics 
(Giraudon et al., 2013). In addition, a substantial number of 
deaths involve polydrug use, particularly heroin in combination 
with other central nervous system depressants, such as 
alcohol or benzodiazepines.
A number of environmental factors increase the risk of 
drug overdose death, including in the case of opioid users, 
disruption of treatment provision or discontinuity of treatment 
and care. And in certain situations, for example following 
detoxification or discharge from drug-free treatment, the 
tolerance of drug users to opioids is greatly reduced and as 
a result they are at particularly high risk of overdosing. For 
these same reasons, inadequate throughcare between prison 
and community has also been identified as an important 
environmental risk factor (Zlodre and Fazel, 2012).
Finally, the lack of response or inadequate interventions by 
those witnessing overdoses, whether due to poor first aid 
knowledge, lack of access to effective medication or fear of 
legal repercussions, increases the risk of an overdose event 
having a fatal outcome (Frisher et al., 2012).
I  A range of responses: reducing the number of overdoses and preventing deaths
Drawing on the insights gained from risk and protective 
factors, the prevention of overdose deaths is generally 
addressed at two levels: the first involves a set of interventions 
geared towards the complete prevention of overdoses, 
while the second focuses on reducing fatal outcomes when 
overdoses do occur (Frisher et al., 2012). At both levels, 
strategies used include the scaling-up of known protective 
factors and the reduction of existing risks. Below, we introduce 
some of the most important strategies use by countries to 
address these intervention levels. 
Increasing awareness of and information about overdose risks
As many drug users either are unaware of or seriously 
underestimate overdose risks, effective communication with 
users can act as a catalyst for reducing harm. Ideally, overdose 
prevention, education and counselling interventions would 
be provided by trained professionals as a matter of routine in 
the relevant health and primary care settings. Screening for 
overdose risk by those treating heroin users may contribute to 
reductions in overall mortality (Darke et al., 2011), while the 
use of overdose risk assessment interventions can assist the 
early identification of high-risk individuals.  
28 EMCDDA reporting countries now report the distribution of 
overdose risk information, which is sometimes also available 
in different languages, in order to reach migrant drug users. 
There is increasing use of the Internet and new channels of 
communication in this field, for example an e-health overdose 
risk assessment tool and overdose awareness videos, which 
may be projected in the waiting rooms of drugs facilities  
(e.g. http://vimeo.com/album/1655129). Acknowledging the 
similarity of trends in mortality related to prescription opioids 
in Europe to those witnessed in the US, countries now have an 
opportunity to adapt and scale up their prevention measures, 
reinforce surveillance and introduce improved regulatory 
measures to prevent deaths reaching epidemic proportions 
(Giraudon et al., 2013).
Provision of effective drug treatment and retention in 
treatment
There is convincing evidence that opioid substitution 
treatment (OST) substantially reduces the risk of mortality, 
as long as doses are sufficient and continuity of treatment 
is maintained (e.g. Degenhardt et al., 2011). A prospective 
observational cohort study conducted in Edinburgh recently 
confirmed that survival is increased by cumulative exposure to 
treatment (Kimber et al., 2010). As retention in drug treatment 
is a protective factor against overdose deaths, many European 
countries have given priority to increasing access to and 
coverage of treatment services.
With OST provision high, medical staff and service planners 
face the challenge of minimising the diversion of substitution 
medications to those without prescriptions while continuing 
to ensure that access to treatment is not impeded. Another 
widely used approach to reduce the risk of overdose is the 
implementation of good treatment practice, which involves the 
use of clinical guidelines and training doctors in prescribing 
practices (including benzodiazepine prescribing).
I  Facts and figures 
1.3 million problem opioid users in Europe
6 100 overdose deaths in 2013
More than 70 000 overdose deaths during the first decade 
of the 21st century
3.4 % of all deaths in adult males under 40
730 000 clients in opioid substitution treatment in 2013
7 countries with take-home naloxone programmes
8 countries, including Switzerland, with drug consumption 
rooms
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Improving throughcare between prison and community
Several interventions are recommended to help reduce the 
high numbers of overdose deaths among former prisoners 
in the period shortly after leaving prison (Merrall et al., 2010; 
Binswanger et al., 2013).  (Merrall et al., 2010; Binswanger et 
al., 2013). These include pre-release education on overdose 
risks and prevention, continuation and initiation of substitution 
treatment and improved referral to aftercare and community 
treatment services (WHO, 2010). A randomised trial (N-ALIVE 
trial) is under way to test the hypothesis that giving naloxone 
on release to prisoners with a history of heroin injecting will 
reduce heroin overdose deaths in this population during the 
most risky period — the first 12 weeks after release (Strang et 
al., 2013). 
I  Prevention of deaths in overdose situations
A second set of responses focuses on the prevention of 
fatalities when overdoses occur. These include a range of 
targeted interventions, the purpose of which is to enhance 
safety and ensure a rapid and effective response in emergency 
situations.
 Supervised drug consumption rooms
A total of 74 facilities for supervised drug consumption 
operate across five Member States and Norway, serving 
specific subgroups of highly marginalised and homeless 
drug users. Supervised drug consumption facilities aim 
to reach marginalised high-risk drug users and connect 
them to the wider network of care, to reduce acute risks of 
diseases and overdose death associated with injecting or 
inhalative drug use, and to reduce public drug use (EMCDDA, 
2015). Consumption rooms are highly targeted services, 
usually integrated within facilities that offer a broad range 
of other health and social services. They provide a safer 
drug use environment, advice on safer injecting and medical 
supervision, and are equipped to manage drug overdoses 
and reduce related morbidity and mortality. Millions of 
injections have been supervised and no overdose fatalities 
have occurred in the facilities. Evidence from robust studies 
document increased access to health and social services 
among clients of supervised drug consumption facilities as 
well as decreased public drug use and associated nuisance. 
A reduction in overdose mortality at population level was 
documented in the local area in the city of Vancouver, where 
a supervised injecting facility operates (Marshall et al., 2011). 
See also, Drug consumption rooms (EMCDDA Perspectives on 
Drugs, 2015).
 
Improved bystander response
Most overdoses occur when others are present and most 
injecting drug users have witnessed or experienced 
overdoses. Therefore, drug users themselves, or their friends 
and family, are likely to be both bystanders and potential 
first responders in emergency overdose situations (Strang et 
al., 2008). These human networks, with appropriate training 
and awareness raising, can be utilised to prevent overdose 
deaths. Interventions that aim to improve bystander responses 
consist of training peers and family members of drug users in 
overdose prevention, recognition and response. In their new 
guidelines on community management of opioid overdose, the 
Word Health Organization recommends that people likely to 
witness an opioid overdose should have access to naloxone 
— an effective antidote that can reverse opioid intoxication — 
and should be instructed in its administration (WHO, 2014). 
Evidence shows that educational and training interventions 
for peers and family members, complemented by take-home 
naloxone, help decrease overdose-related mortality (EMCDDA, 
2015). In October 2014, the EMCDDA brought together 
naloxone projects for a Europe-wide exchange of knowledge 
and experience. 
I  Conclusions
Drug overdose deaths are preventable, and there is good 
evidence to show that specific interventions can both reduce 
the occurrence of overdose events and prevent fatal outcomes 
in overdose situations. Although the overall numbers of drug-
induced deaths remain high, Europe has seen some positive 
trends and developments in recent years. The accumulated 
knowledge about risk and protective factors associated 
with overdoses, and about the successful management of 
overdose situations, has grown. 
PERSPECTIVES ON DRUGS I Preventing overdose deaths in Europe
Naloxone (Narcan®) is an opioid antagonist medication 
used worldwide in emergency medicine to reverse 
respiratory depression caused by opioid overdose. 
Naloxone is listed by the World Health Organization as 
an essential medicine and is available in injectable form 
(intramuscular and intravenous) and in some countries 
as an intranasal spray. The effectiveness of concentrated 
intranasal naloxone has been shown to be similar to that of 
intramuscular naloxone as a first-line treatment for heroin 
overdose (Kerr et al., 2009). Community-based opioid 
overdose prevention programmes which combine naloxone 
distribution by training potential bystanders, such as opioid 
users and their peers and family on how to administer the 
drug in order to reverse the effects of opioid overdose are 
among the range of overdose prevention responses in the 
US and Europe (CDC, 2012; Clark et al., 2014; Williams et 
al., 2014).  
 
A recent EMCDDA systematic review of the available studies 
on take-home naloxone concludes: ‘There is evidence from 
one interrupted time-series study, involving 2 912 opioid 
users at risk of overdose in 19 communities followed up 
for seven years, that educational and training interventions 
complemented by take-home naloxone decrease overdose-
related mortality. There is weaker, but consistent, evidence 
that similar interventions for opioid-dependent patients and 
their peers effectively improve knowledge, while forming 
positive attitudes to the correct use of naloxone and the 
management of witnessed overdoses’ (EMCDDA, 2015). 
 
Currently, seven European countries (Denmark, Estonia, 
Germany, Italy, Norway, Spain and the United Kingdom) 
report the existence of take-home naloxone programmes, 
some of them small and time limited. Scotland and Wales 
run nationwide programmes of naloxone distribution to 
high-risk users in the community and to inmates released 
from prison. Latest data from the national naloxone 
programme in Scotland show a reduction in the rate of 
opioid-related deaths within four weeks of prison release 
to 4.7 % in comparison to the 2006–10 baseline indicator 
of 9.8 % (Information Services Division, 2014).  In some 
countries, legislative reform may be needed to allow the 
low-threshold provision of naloxone, but the measure 
is regarded as a low-cost approach that can empower 
healthcare workers and people who use drugs to save lives 
(WHO, 2014, p.9).
Peer naloxone distribution  
Video: example of an overdose awareness video projected in waiting rooms of 
drugs facilities available on the EMCDDA website: emcdda.europa.eu/topics/pods/
preventing-overdose-deaths
I  Interactive element: videoAccess to OST, which constitutes an important protective 
factor, has been substantially scaled up across the region. In 
addition, some countries have introduced new and targeted 
approaches, searching for innovative ways to identify those 
at risk of overdose, to raise risk awareness and to enable 
those who witness overdoses to intervene and prevent fatal 
outcomes.
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